December 3, 2020 | Jen Temple, Head of Communications | Reading Time: < 1 minute
Canexia Health’s Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. OncLive is a digital platform that offers resources and information to oncology professionals that they can use to help provide the best patient care.
In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
June 15, 2022
MONTRÉAL, June 15, 2022 – Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.
May 19, 2022
Health is becoming digital health, encompassing everything from electronic patient records to telemedicine and mobile health — spurred on by the pandemic. But the next evolution will involve artificial intelligence. While the potential of AI is enormous, there are still a number of challenges to delivering impactful solutions for clinical adoption.